The investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV) disease and prevented RSV hospitalizations among healthy preterm- and term infants, according to results of a phase IIb/III study.
A single dose of clesrovimab reduced the incidence of RSV-associated medically attended lower respiratory infections (MALRI) that had at least one indicator of LRI or severity by 60.4% when compared with placebo through 5 months after treatment (95% CI 44.1-71.9, P
Source : MedPageToday